Investment Rating - The industry investment rating is "Outperform the Market" [3][23]. Core Insights - The blood products sector underperformed the market in September, primarily due to short-term performance pressures and changes in market sentiment. Long-term focus should remain on leading companies' plasma stations and R&D progress [1][21]. Summary by Sections Market Review - In September, the pharmaceutical and biological index fell by 1.71%, underperforming the CSI 300 index. The blood products sector specifically declined by 4.86% [1][14]. - Year-to-date, the blood products sector has seen a decline of 7.32% [15]. - Key blood product companies experienced significant stock price drops in September, with declines ranging from 2.76% to 8.59% [19]. Monthly Perspective on Blood Products - The decline in blood product stock prices since the beginning of 2025 is attributed to short-term performance pressures and market sentiment shifts. Price reductions in blood products have led to decreased gross margins and cash flow pressures for companies [21]. - The industry is undergoing accelerated consolidation, with leading companies leveraging mergers and acquisitions to strengthen their market position [21]. - Key areas of focus for the blood products sector include: 1. Plasma station resources and integration capabilities, as upstream plasma resources remain a core barrier to entry [21]. 2. Upgrading product structures to increase the proportion of high-margin products like coagulation factors and new products such as recombinant products and subcutaneous immunoglobulin [21]. 3. Monitoring price changes in blood products over the coming months [21]. 4. Advancements in new technologies for recombinant human serum albumin production using plant or yeast expression systems [21].

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. has received the Drug GMP Compliance Inspection Notice and the updated Drug Production License, indicating the completion of the production site change for the product "Recombinant Human Coagulation Factor VIII" and the potential for expanded production capacity [1][4]. Group 1: GMP Compliance Inspection - Chengdu Rongsheng received the Drug GMP Compliance Inspection Notice from the Sichuan Provincial Drug Administration [1]. - The inspection was conducted from August 18 to August 21, 2025, and concluded that the company complies with the Drug Production Quality Management Standards (2010 revision) and related appendices [2]. Group 2: Drug Production License Changes - The production scope for Chengdu Rongsheng has been updated to include the production of "Recombinant Human Coagulation Factor VIII," limited to registered application use, following the successful GMP compliance inspection [3]. - The production address remains the same: No. 280, Jingyuan Road, Shuangliu District, Chengdu, Sichuan Province [3]. Group 3: Impact on the Company - The product "Recombinant Human Coagulation Factor VIII" was approved for market launch in September 2023, and the production site change was approved in July 2025 [4]. - The completion of the production site change allows for an increase in production scale for the product [4].

证券代码：600161 证券简称：天坛生物 编号：2025-049 北京天坛生物制品股份有限公司 关于下属企业获得《药品GMP符合性检查告知书》及变更 《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司（以 下简称"成都蓉生"）收到四川省药品监督管理局颁发的《药品 GMP 符合性检查 告知书》和变更后的《药品生产许可证》。成都蓉生已完成"注射用重组人凝血 因子Ⅷ"产品生产场地变更工作，可实现该产品生产规模扩大。现就相关情况公 告如下： 一、 《药品 GMP 符合性检查告知书》相关信息 检查时间：2025 年 8 月 18 日-2025 年 8 月 21 日 检查结论：符合《药品生产质量管理规范（2010 年修订）》及相关附录规 定。 发证机关：四川省药品监督管理局 二、 《药品生产许可证》变更内容 同意成都蓉生生产地址四川省成都市双流区菁园路 280 号的生产范围治疗 用生物制品（注射用重组人凝血因子Ⅷ）（仅限注册申报使用）变更为治疗用生 物 ...

Core Viewpoint - TianTan Biological announced that its subsidiary Chengdu Rongsheng Pharmaceutical has received the GMP compliance inspection notice and the updated drug production license from the Sichuan Provincial Drug Administration, allowing for an expansion in the production scale of "Recombinant Human Coagulation Factor VIII" [1] Group 1 - Chengdu Rongsheng has completed the site change for the production of "Recombinant Human Coagulation Factor VIII" [1] - The GMP compliance inspection was conducted from August 18 to August 21, 2025, and concluded that the company meets the relevant regulations [1] - The updated drug production license allows for the production of therapeutic biological products (Recombinant Human Coagulation Factor VIII) at the new address in Chengdu, Sichuan Province [1]

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary, Kunming Blood Products Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration for the clinical trial of "Human Fibrinogen" [1] Group 1: Product Information - The product "Human Fibrinogen" is set to undergo clinical trials following the approval [1] Group 2: Market Situation - The domestic market information is sourced from the National Medical Products Administration's official website [1] - International market details were not disclosed in the announcement [1] Group 3: Approval Process - The product must complete several steps including clinical trials, submission of drug marketing authorization application, review by the National Medical Products Administration, and obtaining a drug registration certificate before it can be produced and marketed [1]

Group 1 - The Financial Regulatory Administration released guidelines to promote the high-quality development of health insurance, focusing on enhancing industry foundations, improving professional capabilities, accelerating digital transformation, and supporting innovative payment methods for new drugs and medical devices [1][5] - The Ministry of Finance and the Ministry of Commerce will initiate pilot projects in around 50 cities to stimulate high-quality consumption, addressing issues like insufficient supply and innovation in consumption sectors [1][5] - The National Development and Reform Commission announced the allocation of 69 billion yuan in special bonds to support the consumption upgrade program, completing the annual target of 300 billion yuan [1][5] Group 2 - The China Securities Regulatory Commission held a meeting to discuss the "14th Five-Year" capital market plan, suggesting reforms in areas like issuance, refinancing, and mergers to enhance market attractiveness and inclusivity [1][5] - The Shanghai and Shenzhen Stock Exchanges announced that qualified foreign investors can participate in ETF options trading, limited to hedging purposes [1][5] - The Ministry of Ecology and Environment is seeking public opinion on the carbon emissions trading market allocation plan for the steel, cement, and aluminum industries for 2024 and 2025, emphasizing free allocation based on carbon emissions per unit output [1][5] Group 3 - The latest data from the National Bureau of Statistics indicates that the manufacturing PMI rose to 49.8% in September, reflecting continued improvement in manufacturing activity [1][5] - The latest report from the National Foreign Exchange Administration shows that China's external debt remained stable at 24,368 billion USD as of June 2025, with a slight decrease of 0.6% from March 2025 [1][5] - The U.S. consumer confidence index fell to 94.2 in September, marking the lowest level since April, according to a report from the Conference Board [2][5]

Core Viewpoint - TianTan Biological announced the approval of a clinical trial for "human fibrinogen" by the National Medical Products Administration [1] Group 1 - TianTan Biological's subsidiary, Kunming Blood Products Co., Ltd., received the clinical trial approval notice [1] - The approval allows the company to conduct clinical trials for "human fibrinogen" [1]

Core Viewpoint - Tian Tan Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of "human fibrinogen" [1] Group 1 - Tian Tan Kunming, a subsidiary of Tian Tan Biological, is authorized to conduct clinical trials for "human fibrinogen" [1]

Core Viewpoint - Tian Tan Biological (600161.SH) has received approval from the National Medical Products Administration for clinical trials of its "human fibrinogen" product, marking a significant step towards potential market entry [1] Group 1 - Tian Tan Biological's subsidiary, China National Pharmaceutical Group Kunming Blood Products Co., Ltd. (referred to as "Tian Tan Kunming"), has been granted the Clinical Trial Approval Notice for "human fibrinogen" [1] - The product will need to complete clinical trials, submit a drug marketing authorization application, pass the review by the National Medical Products Administration's Drug Evaluation Center, and obtain a drug registration certificate before it can be produced and sold [1]

Core Viewpoint - Tian Tan Biological (600161.SH) has received approval from the National Medical Products Administration for clinical trials of its "human fibrinogen" product, marking a significant step towards potential market entry [1] Group 1: Company Developments - Tian Tan's subsidiary, Kunming Blood Products Co., Ltd., has been granted the Clinical Trial Approval Notice for "human fibrinogen" [1] - The company must complete several steps, including conducting clinical trials, submitting a drug marketing application, and obtaining necessary approvals before production and sales can commence [1] Group 2: Regulatory Environment - The approval from the National Medical Products Administration is a crucial regulatory milestone for the company [1] - The process includes clinical trials, review by the drug evaluation center, and final approval from the National Medical Products Administration [1]